Atossa Genetics

Atossa Genetics
Public
Traded as NASDAQ: ATOS
Industry Biotechnology
Founded 2009
Founder Dr. Steven Quay
Headquarters Seattle, Washington
Key people
 Dr. Steven Quay (CEO)
Products Breast Cancer Pharmaceuticals
Website www.atossagenetics.com

Atossa Genetics NASDAQ: ATOS is a Seattle-based healthcare firm that specializes in breast health.[1][2][3][4] The company focuses on the development and marketing of pharmaceuticals for the treatment of breast cancer.[1][2][3][4]

The company is named after the Persian Queen Atossa, who became the first woman in recorded history with breast cancer around 470 B.C.[1][2][5][6]

History

In 2000, Dr. Steven Quay, a physician specializing in biological chemistry, invented a preventative screening method to identify precursors to breast cancer and to treat precancerous lesions.[1][2][4][6] In May 2016, Dr. Quay and Dr. Shu-Chih Chen, Ph.D. had published the book, “Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers: Current Role in the Management of Breast Health,” which describes the status of research and clinical practice involving the Atossa technology.

Quay founded Atossa Genetics in 2009.[7] The company went public and became listed on the NASDAQ stock exchange under the symbol ATOS in 2012.[8] In January 2013, Atossa launched the ForeCYTE Breast Health Test system. Atossa voluntarily recalled the system following an FDA warning letter that stated it needed additional FDA clearance due to changes made to the system following the FDA's prior approval.[9]

Atossa Genetics is sponsoring a Phase 2 clinical trial,[10] on the use of fulvestrant administered through a microcatheter into the lactiferous duct as neoadjuvant treatment for ductal carcinoma in situ and invasive breast cancer.

References

  1. 1 2 3 4 "Overview". Atossa Genetics. Retrieved 18 June 2014.
  2. 1 2 3 4 "Atossa Genetics Inc (ATOS) IPO". NASDAQ. Retrieved 18 June 2014.
  3. 1 2 "Atossa Genetics completes $6.6M financing round". FinSMEs. 27 June 2011. Retrieved 18 June 2014.
  4. 1 2 3 "Atossa Genetics Inc.". The New York Times. Retrieved 18 June 2014.
  5. ↑ Beth Potter (5 August 2011). "Atossa gearing up to sell breast-cancer detection device". Puget Sound Business Journal. Retrieved 18 June 2014.
  6. 1 2 "Atossa Genetics Inc.". Securities & Exchange Commission. 3 October 2012. Retrieved 18 June 2014.
  7. ↑ Luke Timmerman (21 May 2010). "Who Needs VCs? Steven Quay's Atossa Genetics Seeks Fast IPO For Breast Cancer Test". Xconomy. Retrieved 18 June 2014.
  8. ↑ Drew DeSilver (8 November 2012). "Seattle's Atossa Genetics completes pint-size IPO". The Seattle Times. Retrieved 18 June 2014.
  9. ↑ "Atossa recalls breast health device, shares tumble". Reuters. 4 October 2013. Retrieved 18 June 2014.
  10. ↑ "PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy". Clinicaltrials.gov. 28 August 2015.

External links

This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.